Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis. 2011;3(1):e201103.Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other "good risk...
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica, 94 (1) (2009), pp. 102-112 CrossrefVie...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (nonacute promyelocytic leukemia) diagnosed in 1997 to 20...
Secondary acute leukemia (sAL) is a well-recognized complication of cytotoxic and radiation therapy in breast cancer with a 5-year incidence ranging from 0.3% to 1.2%. The risk of developing leukemia in breast cancer patients may be related to their favourable life expectancy, wide use of ...
Takeuchi M, Yamauchi T, Yoshida I, et al.: Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. Int J Hematol 2003,77(2):196–198. 10.1007/BF02983222 Article PubMed Google Scholar Lindner LH, Osterm...
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica 2009; 94: 102–112. Article Google Scholar ...
A total of 197 patients with non-acute promyelocytic leukemia(non-APL)(119 males and 78 females) were also included. The median age of non-APL patients was 70 years(average 67, range 24-95). The 5-year OS rate was 21.1%. Subsequent analysis by age group showed that the survival rate...
Acute promyelocytic leukemiaRetinoic acid receptor-αPML/RARαAll-transretinoic acidWnt/β-catenin pathwayAXLReceptor tyrosine kinaseBackground Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia (AML) which is characterized by the fusion of promyelocytic leukemia PML and retinoic ...
Another remarkable example is the combination therapy for acute promyelocytic leukemia with ATRA and arsenic trioxide which leads to complete and long-lasting remission in more than 90% of all patients. Interestingly, this treatment not only restores the differentiation-promoting function of the RAR ...